2010
DOI: 10.1007/s10067-010-1402-x
|View full text |Cite
|
Sign up to set email alerts
|

Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-α blockade

Abstract: Chronic inflammation in ankylosing spondylitis (AS) is associated with vascular endothelial dysfunction. Infliximab improves inflammatory disease activity in AS patients, but its effect on endothelial dysfunction has still not been tested in these patients. Twelve anti-TNF naive AS patients (mean age, 32.6 +/- 3.94 years; disease duration, 5.6 +/- 0.8 years) with high disease activity [Bath ankylosing spondylitis disease activity index (BASDAI score > 4)] despite treatment with stable doses of conventional dis… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
23
0
2

Year Published

2013
2013
2018
2018

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 52 publications
(26 citation statements)
references
References 41 publications
0
23
0
2
Order By: Relevance
“…103 Decreased FMD correlates well with invasive tests of coronary endothelial dysfunction and atherosclerosis, and predicts CV events in population-based studies. 104,105 In patients with inflammatory arthritis, most studies revealed transient [106][107][108][109] or even sustained ($12 weeks) [110][111][112][113][114][115] improvement in macrovascular function by anti-TNF treatment, whereas only 3 studies found no improvement. 75,95,116 In a study comparing anti-TNF treatment and traditional DMARDs, more significant improvement in FMD was observed in the anti-TNF group.…”
Section: Mechanism Of Inflammation In Cvd In Inflammatorymentioning
confidence: 98%
“…103 Decreased FMD correlates well with invasive tests of coronary endothelial dysfunction and atherosclerosis, and predicts CV events in population-based studies. 104,105 In patients with inflammatory arthritis, most studies revealed transient [106][107][108][109] or even sustained ($12 weeks) [110][111][112][113][114][115] improvement in macrovascular function by anti-TNF treatment, whereas only 3 studies found no improvement. 75,95,116 In a study comparing anti-TNF treatment and traditional DMARDs, more significant improvement in FMD was observed in the anti-TNF group.…”
Section: Mechanism Of Inflammation In Cvd In Inflammatorymentioning
confidence: 98%
“…Regarding therapeutic strategies for the treatment of AS, anti-TNF- α therapy was found to be effective to treat patients with this disease [5–7]. Anti-TNF- α agents lead to a suppression of inflammation and thus to a reduction of disease activity, as well as to an improvement of endothelial function in AS patients [8, 9]. This is the reason why the assessment of new potential CV risk biomarkers and the influence of anti-TNF- α therapy on them could shed light on the biologic mechanisms of these biologic agents associated with atherosclerosis in AS patients.…”
Section: Introductionmentioning
confidence: 99%
“…177,181 Beneficial effects on capillary recruitment and endotheliumdependent vasodilatation were also reported in ankylosing spondylitis patients treated either with etanercept, 178 or with infliximab, which was furthermore shown to reduce nitrite concentrations. 182 In contrast, Irace et al reported transient vasoconstriction and increased wall shear stress in the common carotid and brachial arteries following treatment with infliximab in patients with rheumatoid arthritis, with no effect on flow-mediated dilatation. 183 Progression of atherosclerosis in psoriatic arthritis patients despite TNF-α blockade was also observed; these patients showed no recovery of flow-mediated dilatation after 2 years of anti-TNF-α treatment, and their serum TNF-α levels were increased at 2 years when compared with baseline.…”
Section: Tnf-α Antagonism In Autoimmune Diseasesmentioning
confidence: 95%